5-Azacitidine in patients with IDH1/2-mutant recurrent glioma

Neuro Oncol. 2020 Aug 17;22(8):1226-1228. doi: 10.1093/neuonc/noaa074.

¹ Pharmacy Clinical Service, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France.
² Department of Neurosurgery, University Hospitals of Pitié Salpêtrière‒Charles Foix, Paris, France.
³ Sorbonne University, Institute of the Brain and Spinal Cord, Department of Neurosurgery, University Hospitals of Pitié Salpêtrière‒Charles Foix, Neuropathology Service, Paris, France.
⁴ Département d'Hématologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
⁵ INSERM Unit 1170, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France.
⁶ Sorbonne University, Institute of the Brain and Spinal Cord, Department of Neurosurgery, University Hospitals of Pitié Salpêtrière‒Charles Foix, Neurology Service 2-Mazarin, Paris, France.
⁷ Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

No abstract available

Publication types